Lupin is currently trading at Rs. 889.90, up by 9.05 points or 1.03% from its previous closing of Rs. 880.85 on the BSE.
The scrip opened at Rs. 898.00 and has touched a high and low of Rs. 900.00 and Rs. 886.75 respectively. So far 1,53,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 807.00 on 06-Dec-2017.
Last one week high and low of the scrip stood at Rs. 900.00 and Rs. 865.10 respectively. The current market cap of the company is Rs. 40,225.00 crore.
The promoters holding in the company stood at 46.80%, while Institutions and Non-Institutions held 40.05% and 13.14% respectively.
Lupin has received final approval for its Calcipotriene Topical Solution, 0.005% (Scalp Solution) from the United States Food and Drug Administration (USFDA) to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products.
Lupin's Calcipotriene Topical Solution, 0.005% (Scalp Solution) is the AT rated generic equivalent of Leo Pharmaceutical Products' Dovonex Scalp Solution, 0.005%. It is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp.
Calcipotriene Topical Solution, 0.005% (Scalp Solution) had annual sales of approximately $5.9 million in the US (IMS MAT October 2017).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.